Portal Biotechnologies, headquartered in Watertown, MA, is a rapidly scaling cell-engineering platform company redefining how scientists and clinicians engineer cells across research, drug discovery, and therapeutic applications. Since launching its first product in 2024, Portal has built a network of 80+ active customers, including most of the top 10 global pharmaceutical companies and leading academic hospitals worldwide. Backed by $14M in venture funding and an $8M DARPA contract, Portal’s proprietary mechanoporation technology transiently perturbs cell membranes as they pass through a silicon microstructure. This enables efficient multiplex delivery of diverse cargos such as RNA, proteins, small molecules, and gene-editing tools without compromising cell function. The approach is simple and scalable, supporting applications from high-throughput drug screening to clinical-scale manufacturing, and it works both as a stand-alone system and as an integrated component in third-party platforms.